- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Samsung Gets FDA Nod for Versatile V7 Ultrasound System
Offering uniform high-resolution images through a combination of beamforming and enhanced image processing, the new ultrasound platform reportedly has an array of diagnostic features ranging from cardiovascular applications to breast lesion assessment.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the V7 Ultrasound system, which provides enhanced, high-resolution imaging for a variety of clinical applications Including cardiovascular and breast imaging, according to Samsung, the manufacturer of the device.
Samsung noted the increased resolution and clarity of imaging with the V7 Ultrasound system stems from Crystal Architecture™, which includes the use of S-Vue Single Crystal Transducers™ and proprietary beamforming (CrystalBeam™) and image processing technologies (CrystalLive™).
The ultrasound platform has a variety of specialized clinical features including the artificial intelligence (AI)-enabled UterineAssist™, which provides automated measurements of the uterus; 2D Follicle™, which allows automated measurements of follicles for gynecologic exams; and S-Detect™ for Breast, which assesses breast lesions and applies appropriate BI-RADS ATLAS info to reporting.
“There is a continued demand on imaging professionals to deliver high-quality results in an efficient amount of time without compromising patient care,” noted David Legg, vice president and head of Boston Imaging, the United States headquarters for Samsung’s digital radiography and ultrasound business. “We’re proud to help address this by supplying one more solution that helps make clinical assessments effortless and treatment precise.”
Other clinical measurement tools with the V7 Ultrasound include ArterialAnalysis, which detects functional blood vessel changes; AutoIMT+, which measures the intima-media thickness of the posterior and anterior walls of the common carotid; and AutoEF, which assesses potential ejection fraction through different measurements in the left ventricle, according to Samsung.
Samsung said the V7 Ultrasound device also enables clinicians to get better image quality through technologies such as HQ-Vision™ and ClearVision. The company explained that HQ-Vision reportedly mitigates contributing characteristics to blurry imaging and ClearVision reduces noise with enhanced edge contrast of two-dimensional images.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
September 23rd 2024The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.
Can AI Enhance CT Detection of Incidental Extrapulmonary Abnormalities and Prediction of Mortality?
September 18th 2024Emphasizing multi-structure segmentation and feature extraction from chest CT scans, an emerging AI model demonstrated an approximately 70 percent AUC for predicting significant incidental extrapulmonary findings as well as two-year and 10-year all-cause mortality.
